Actively Recruiting

Age: 18Years +
All Genders
Healthy Volunteers
ID07069556

ColoSense Post Approval Study for Colorectal Cancer Detection

Led by Geneoscopy, Inc. · Updated on 2025-11-21

12500

Participants Needed

1

Research Sites

104 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the ColoSense multi-target stool RNA test in a post-approval study to supplement existing data from a previous clinical trial. This observational study focuses on measuring clinical sensitivity, clinical specificity, positive predictive value, and negative predictive value of ColoSense in detecting colorectal cancer and related conditions. The study helps to better understand the accuracy of the test in a real-world setting. Participants will provide stool samples within 120 days before undergoing a colonoscopy. The study does not involve experimental treatments but observes the performance of ColoSense compared to colonoscopy findings over an average of 5 years. No investigational drugs or placebos are involved, as this is an observational device study. During the study, participants will undergo colonoscopy and provide stool samples as part of routine clinical care. Researchers will track outcomes such as colorectal cancer sensitivity, advanced adenoma sensitivity, serrated polyp sensitivity, and negative specificity over the study period. The study includes adults aged 18 and older, with follow-up continuing through study completion to monitor test accuracy and safety.

CONDITIONS

Brief Title

ColoSense Post-Approval Study

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Subject is male or female, 45 years of age or older (subjects aged 18-45 can be enrolled but are not eligible for primary endpoint analysis)
  • Subject is able to understand study procedures and provide consent
  • Subject authorizes release of relevant protected health information
  • Subject is able and willing to provide stool samples within 120 days prior to colonoscopy
  • Subject is able and willing to undergo colonoscopy after providing stool sample
Not Eligible

You will not qualify if you...

  • Subject had any precancerous findings on most recent colonoscopy excluding benign or hyperplastic polyps
  • Subject has history or diagnosis of colorectal cancer
  • Subject has history of aerodigestive tract cancer
  • Subject had positive non-invasive screening test within recommended intervals (fecal occult blood or immunochemical test within 12 months, FIT-DNA test within 36 months)
  • Subject had colonoscopy within previous 9 years
  • Subject had prior colorectal resection except for sigmoid diverticular disease
  • Indication for colonoscopy was overt rectal bleeding within previous 30 days (blood on toilet paper does not count)
  • Subject has diagnosis or history of high-risk colorectal cancer conditions including inflammatory bowel disease, familial adenomatous polyposis, hereditary non-polyposis colorectal cancer syndrome, or other hereditary cancer syndromes listed in criteria

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - Up to 120 days before colonoscopy

Participants provide stool samples for the ColoSense multi-target stool RNA test prior to undergoing colonoscopy.

1 visit for stool sample collection

Diagnostic Evaluation

Duration - 1 day

Participants undergo colonoscopy to evaluate colorectal health following stool sample collection.

1 visit (in-person)

Long-term Monitoring

Duration - Approximately 5 years

Participants are monitored for colorectal cancer detection outcomes over an average of 5 years through study completion.

Periodic assessments as per routine care

Trial Site Locations

Total: 1 location

1

Decentralized Study

St Louis, Missouri, United States, 63146

Actively Recruiting

Loading map...

Research Team

E

Erica K Barnell, MD PhD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

Study of ABT-301 With Tislelizumab and Bevacizumab in pMMR/N...

Colorectal Cancer (Diagnosis)

Actively Recruiting

15 locations

Effects of High-Fiber Diet on Gut Microbiota, Metabolism, an...

Colorectal Cancer (Diagnosis)

Actively Recruiting

1 location

Evaluating the Implementation of a Comprehensive Multilevel ...

Lung Cancer Diagnosis

Actively Recruiting

5 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here